Is Bacillus subtilis 35624 a real probiotic strain?

No, 'Bacillus subtilis 35624' does not appear in any peer-reviewed clinical research or established strain repositories such as ATCC or DSMZ. The 35624 strain number is internationally recognized as belonging to Bifidobacterium longum 35624, the active ingredient in Align probiotic. Any supplement labeling Bacillus subtilis 35624 likely contains a mislabeled or fictional strain designation.

What is the difference between Bacillus subtilis and Bifidobacterium longum 35624?

Bacillus subtilis is a spore-forming, gram-positive rod bacterium primarily found in soil and the gastrointestinal tract, known for producing enzymes and antimicrobial lipopeptides. Bifidobacterium longum 35624 is an anaerobic lactic acid bacterium residing in the human colon that modulates immune responses via dendritic cell interaction and regulatory T-cell promotion. These are entirely different genera with distinct mechanisms, research bodies, and clinical applications.

What are the actual benefits of Bifidobacterium longum 35624?

Bifidobacterium longum 35624 has clinical evidence supporting its use in irritable bowel syndrome (IBS), with randomized controlled trials demonstrating significant reductions in abdominal pain, bloating, and bowel dysfunction scores versus placebo. It works by producing short-chain fatty acids, modulating mucosal immune responses, and reducing pro-inflammatory cytokines such as TNF-α. The typical studied dose is 1×10⁸ to 1×10⁹ CFU per day.

Are there any legitimate Bacillus subtilis probiotic strains with research support?

Yes, several Bacillus subtilis strains have documented research, including DE111 (studied at 1×10⁹ CFU/day for gut microbiome modulation and cholesterol support in small human trials) and Bacillus subtilis PB6, which has shown antimicrobial properties against Clostridium perfringens in animal models. These strains produce surfactin and iturin lipopeptides that disrupt pathogen biofilms. However, findings from these strains cannot be extrapolated to any product labeled 'Bacillus subtilis 35624.'

Should I buy a supplement labeled Bacillus subtilis 35624?

Purchasing a supplement labeled 'Bacillus subtilis 35624' is not recommended because no such validated strain exists in clinical literature or recognized culture collections, meaning no safety, efficacy, or dosing data supports it. This designation suggests either a labeling error, strain misidentification, or a marketing fabrication. Consumers should look for supplements that list full strain designations traceable to established repositories such as ATCC, DSMZ, or NCIMB and that have published human clinical trial data.

Why do some supplements list Bacillus subtilis 35624 when this strain doesn't exist in research?

Bacillus subtilis 35624 appears to be a mislabeling or confusion with Bifidobacterium longum 35624, which is the only clinically studied strain bearing the 35624 designation. Some manufacturers may intentionally or accidentally mix up the two organisms to market their products, exploiting the 35624 strain's established research reputation. This is a red flag for product quality and accuracy, as legitimate probiotic supplements should correctly identify their actual bacterial strains.

How can I verify that a probiotic supplement contains the strain it claims on the label?

Look for supplements with third-party testing certifications (USP, NSF, or ConsumerLab), which verify the actual strain identity and CFU count listed on the label. The product should clearly specify the bacterial species, strain number, and manufacturing country, with the strain name matching published clinical research. Contact the manufacturer directly to request documentation of their strain identity, as legitimate companies can provide verification through genetic sequencing or reference to specific clinical studies.

What Bacillus subtilis strains actually have clinical research support, and how do they compare to Bacillus subtilis 35624?

Bacillus subtilis strains with preliminary research support include DSM 15544 (PLSSC) and other soil-based isolates, but their evidence is far more limited than established probiotic species like Bifidobacterium longum. Bacillus subtilis 35624 has no clinical research whatsoever, making it impossible to compare to evidence-backed strains. If you're considering a B. subtilis probiotic, seek products with documented strain-specific studies rather than generic Bacillus claims or misidentified strain numbers.

Bacillus subtilis 35624

Bacillus subtilis 35624 is a strain designation that does not correspond to any documented Bacillus subtilis isolate in peer-reviewed clinical literature; the '35624' identifier is actually associated with Bifidobacterium longum 35624, a well-researched probiotic strain. Consumers and formulators should verify strain nomenclature carefully, as misattribution can lead to incorrect efficacy and safety expectations.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Traditional

Bacillus subtilis 35624 — Hermetica Encyclopedia

Origin & History

Bacillus subtilis 35624 does not exist in scientific literature - the strain designation 35624 refers to Bifidobacterium longum 35624, a completely different bacterial species. Bacillus subtilis is a gram-positive, rod-shaped bacterium naturally found in soil and the human gut. Various B. subtilis strains (such as PLSSC, CU1, and DSM 29784) have been studied as probiotics, but none carry the 35624 designation.

Historical & Cultural Context

The research dossier does not provide historical or cultural context for Bacillus subtilis usage. The confusion with strain 35624 appears to be a modern nomenclature error, as this designation belongs exclusively to Bifidobacterium longum in clinical literature.

Health Benefits

• No specific health benefits can be attributed to 'Bacillus subtilis 35624' as this strain does not exist in clinical research
• Other B. subtilis strains have shown probiotic properties (evidence quality: preliminary for specific strains mentioned)
• The 35624 strain designation belongs to Bifidobacterium longum, which has over 25 years of clinical research
• Various B. subtilis strains (PLSSC, CU1, DSM 29784) have been studied separately for probiotic applications
• No clinical trials or meta-analyses exist for the non-existent 'Bacillus subtilis 35624' combination

How It Works

No mechanism of action can be accurately attributed to 'Bacillus subtilis 35624' because this specific strain has no documented existence in scientific literature. The '35624' designation belongs to Bifidobacterium longum 35624, which modulates gut immunity via dendritic cell interaction, promoting regulatory T-cell differentiation and suppressing pro-inflammatory cytokines such as TNF-α and IL-6 through TLR2/TLR4 pathway signaling. Other validated Bacillus subtilis strains produce subtilisins, polyglutamic acid, and lipopeptides that support gut barrier integrity via mucin upregulation and competitive exclusion of pathogens.

Scientific Research

No clinical trials or meta-analyses exist for 'Bacillus subtilis 35624' as this strain designation is incorrect. The research dossier confirms that strain 35624 refers specifically to Bifidobacterium longum 35624, which has extensive clinical validation for IBS management. Various other B. subtilis strains have been studied independently, but none carry the 35624 designation.

Clinical Summary

No clinical trials exist for a strain designated 'Bacillus subtilis 35624,' making any efficacy claims for this specific designation unsupported. Bifidobacterium longum 35624 (the correct owner of the 35624 designation) has been studied in randomized controlled trials involving patients with irritable bowel syndrome, with one landmark trial of 77 patients showing significant improvement in quality-of-life scores (p<0.05) versus placebo. Legitimate Bacillus subtilis strains such as DE111 have preliminary human data supporting gut microbiome modulation at doses of 1×10⁹ CFU/day, but these findings cannot be extrapolated to any 'B. subtilis 35624' product. Overall evidence for Bacillus subtilis as a probiotic genus is early-stage and strain-specific.

Nutritional Profile

As a probiotic/fermented ingredient, Bacillus subtilis 35624 does not contribute meaningful macronutrients (carbohydrates, fats, or proteins) in nutritional terms at typical supplemental doses (approximately 1×10⁸ to 1×10⁹ CFU per serving). The dry cell mass of B. subtilis broadly contains approximately 50-60% protein by dry weight (largely intracellular, not bioavailable to the host), ~15-20% carbohydrates (primarily cell wall peptidoglycan and teichoic acids), and ~10-15% lipids (membrane phospholipids including branched-chain fatty acids characteristic of Bacillus species, such as iso-C15:0 and anteiso-C15:0). Bioactive compounds of note in authenticated B. subtilis strains include spore coat proteins, poly-gamma-glutamic acid, and subtilisin-type proteases, though expression profiles for the '35624' designation specifically are unverified. B. subtilis produces menaquinones (Vitamin K2, primarily MK-7) during fermentation, though contribution at probiotic doses is negligible (<1 µg per dose). CRITICAL NOTE: The strain designation '35624' is clinically and commercially associated with Bifidobacterium longum 35624 (formerly B. infantis 35624), not Bacillus subtilis. If mislabeled, Bifidobacterium longum 35624 nutritional profile would differ significantly, being a gram-positive anaerobe with documented exopolysaccharide production. No peer-reviewed compositional data exists specifically for a validated 'Bacillus subtilis 35624' strain, making precise nutritional characterization impossible; values cited reflect genus-level Bacillus subtilis data only.

Preparation & Dosage

No clinically studied dosage ranges exist for 'Bacillus subtilis 35624' as this strain does not exist. Different B. subtilis strains have varying dosage protocols specific to each strain. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot determine synergistic ingredients for non-existent strain

Safety & Interactions

Because 'Bacillus subtilis 35624' is not a documented strain, no strain-specific safety profile, adverse event data, or drug interaction studies exist for it. Generally, Bacillus subtilis-based supplements are considered low-risk in healthy adults, but spore-forming bacteria carry theoretical risks for immunocompromised individuals, including rare reports of bacteremia in vulnerable populations. Probiotic supplements broadly may interact with immunosuppressant medications such as cyclosporine and corticosteroids by unpredictably modulating immune responses. Pregnant and breastfeeding individuals should consult a healthcare provider before using any probiotic with an unverified strain designation, as safety data would be absent.